imatinib has been researched along with ponatinib in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (65.22) | 24.3611 |
| 2020's | 8 (34.78) | 2.80 |
| Authors | Studies |
|---|---|
| Beck, ME; Braun, CA; Getlik, M; Grütter, C; Gutbrod, O; Mayer-Wrangowski, SC; Pérez-Martín, J; Rauh, D; Richters, A; Schreier, PH; Simard, JR | 1 |
| Bai, Y; Ding, K; Feng, Y; Lang, X; Leng, F; Li, Y; Liu, J; Long, H; Lu, X; Luo, J; Pan, J; Pan, X; Ren, X; She, M; Tu, Z; Wang, D; Wen, D; Zhang, F; Zhang, Z; Zhuang, X | 1 |
| Hong, S; Hong, SS; Kim, J; Lee, H; Park, Y; Yun, SM | 1 |
| Bauer, S; Getlik, M; Grütter, C; Gupta, A; Heuckmann, JM; Heynck, S; Ketzer, J; Rauh, D; Richters, A; Schneider, R; Schultz-Fademrecht, C; Sos, ML; Thomas, RK; Unger, A | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bender, S; Glicksman, MA; Kang, S; Lin, R; Liu, M; Ray, S | 1 |
| Choi, BS; Hong, S; Hong, SS; Kim, J; Kim, SJ; Lee, H; Lee, S | 1 |
| Ding, K; Lu, X; Luo, J; Pan, X; Ren, X; Wang, D; Yu, R; Zhang, Z; Zhuang, X | 1 |
| Bai, C; Chen, Y; Ding, K; Ding, Y; Geng, Y; Li, LY; Liu, JW; Sang, F; Sun, B; Sun, J; Wang, J; Wu, LL; Yang, G; Zhang, Q; Zhang, Z | 1 |
| Beleh, OM; Brandvold, KR; Johnson, TK; Kwarcinski, FE; Meagher, JL; Phadke, S; Seeliger, MA; Soellner, MB; Stuckey, JA | 1 |
| Bestgen, B; Borjini, N; Chevé, G; Daydé-Cazals, B; Fauvel, B; Feneyrolles, C; Gassiot, F; Singer, M; Spenlinhauer, A; Van Hijfte, N; Warnault, P; Yasri, A | 1 |
| Jahnke, W; Skora, L | 1 |
| Bauer, S; Ehrt, C; Giordanetto, F; Hardick, J; Kaitsiotou, H; Ketzer, J; Keul, M; Koch, O; Krüll, J; Medda, F; Mühlenberg, T; Rauh, D | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Berellini, G; Buonamici, S; Cotesta, S; Cowan-Jacob, SW; Dodd, S; Drueckes, P; Fabbro, D; Furet, P; Gabriel, T; Groell, JM; Grotzfeld, RM; Hassan, AQ; Henry, C; Iyer, V; Jahnke, W; Jones, D; Lombardo, F; Loo, A; Manley, PW; Marzinzik, AL; Pellé, X; Rummel, G; Salem, B; Schoepfer, J; Warmuth, M; Wylie, AA; Zoller, T | 1 |
| Ding, K; Lu, X; Smaill, JB | 1 |
| Gao, H; Qiu, Y; Rao, Y; Sun, X; Sun, Y; Weng, Q; Yang, Y | 1 |
| Caballero, E; García-Cárceles, J; Gil, C; Martínez, A | 1 |
| Li, Y; Li, Z; Liu, N; Pan, X; Shan, Y; Wang, K; Zhang, J; Zhang, Q | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Hao, RR; Huang, WH; Liang, MH; Pan, YL; Shen, ZR; Zeng, SX | 1 |
| Bruyneel, AAN; Hnatiuk, AP; Malhotra, SV; Mercola, M; Pandrala, M | 1 |
| Allan, JM; Blair, HJ; Dannoura, A; Dueñas, ME; Heidenreich, O; Heunis, T; Inns, J; Marín-Rubio, JL; Martin, MP; Peltier-Heap, RE; Saxty, B; Scott, J; Simpson, AJ; Trost, M; Watt, JE | 1 |
4 review(s) available for imatinib and ponatinib
| Article | Year |
|---|---|
Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.
Topics: Chemistry, Pharmaceutical; Humans; Point Mutation; Protein Kinase Inhibitors | 2020 |
Kinase Inhibitors as Underexplored Antiviral Agents.
Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses | 2022 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2022 |
19 other study(ies) available for imatinib and ponatinib
| Article | Year |
|---|---|
Targeting GSK3 from Ustilago maydis: type-II kinase inhibitors as potential antifungals.
Topics: Amino Acid Sequence; Antifungal Agents; Crystallography, X-Ray; Drug Delivery Systems; Glycogen Synthase Kinase 3; Humans; Molecular Sequence Data; Protein Kinase Inhibitors; Ustilago | 2012 |
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzamides; Biological Availability; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Magnetic Resonance Spectroscopy; Models, Molecular; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Spectrometry, Mass, Electrospray Ionization | 2013 |
Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant.
Topics: Animals; Benzothiazoles; Cell Line; Cell Proliferation; Drug Design; Fusion Proteins, bcr-abl; Mice; Molecular Docking Simulation; Mutation; Nocodazole; Protein Kinase Inhibitors; Protein Structure, Tertiary; Signal Transduction | 2013 |
Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.
Topics: Cell Line, Tumor; Crystallography, X-Ray; Drug Design; Drug Resistance, Neoplasm; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Structure-Activity Relationship | 2013 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity.
Topics: Adenosine Triphosphate; Amino Acid Substitution; Animals; Enzyme Stability; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Models, Biological; Models, Molecular; Mutation, Missense; Parkinson Disease; Phosphorylation; Protein Serine-Threonine Kinases; Protein Structure, Tertiary | 2014 |
Development and biological evaluation of potent and selective c-KIT(D816V) inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Benzamides; Cell Cycle; Cell Line, Tumor; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Indoles; Molecular Docking Simulation; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Structure-Activity Relationship | 2014 |
Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant.
Topics: Cell Proliferation; Fusion Proteins, bcr-abl; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Mutation; Pyrimidines | 2015 |
Structure-Activity Relationship Study of Rakicidins: Overcoming Chronic Myeloid Leukemia Resistance to Imatinib with 4-Methylester-Rakicidin A.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipopeptides; Molecular Structure; Peptides, Cyclic; Structure-Activity Relationship | 2016 |
Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.
Topics: Animals; Chickens; Dasatinib; Drug Design; Humans; Molecular Docking Simulation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Protein Kinases | 2016 |
Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.
Topics: Animals; Cell Proliferation; Drug Design; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Male; Mice; Patch-Clamp Techniques; Protein Kinase Inhibitors | 2016 |
Topics: | 2017 |
Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.
Topics: Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship | 2017 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
Topics: Allosteric Regulation; Animals; Dogs; Drug Discovery; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Models, Molecular; Molecular Structure; Mutation; Niacinamide; Phosphorylation; Protein Conformation; Protein Kinase Inhibitors; Pyrazoles; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects.
Topics: Antineoplastic Agents; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Humans; Imidazoles; Models, Molecular; Niacinamide; Proteolysis; Pyrazoles; Pyridazines | 2020 |
Design, synthesis, and biological evaluation of novel Bcr-Abl
Topics: Alanine; Dose-Response Relationship, Drug; Drug Design; Fusion Proteins, bcr-abl; Humans; Hydroxyproline; K562 Cells; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship | 2021 |
Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors | 2022 |
A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia.
Topics: Cytokines; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inflammation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Proteome; Pyrimidines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2022 |